(MENAFN Editorial) NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled "Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments' published by P & S Market Research, NF-kB inhibitors currently exhibits a strong pipeline with 17 drug candidates.

Request to Get the Sample Pages at:

The study analyzed that the comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation.

According to the National Cancer Institute, the prevalence of cancer has been increasing at a very high rate. Therefore, companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.

Access Report Summary at:

In May 2014, AnGes MG, Inc. and Shionogi & Co., Ltd. entered in a license agreement to co-develop NF-kB decoy oligodeoxynucleotide for the treatment of atopic dermatitis.

Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

Make Enquiry Before Buying:

Browse Related Reports:

Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Analysis 2017

The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF.

BET Inhibitors Pipeline Analysis 2017

In BET inhibitors, IC50 value is measured as the concentration of drug at which 50% of the target is inhibited. IC50 is a pharmacokinetic measure; the lower the IC50 of drug candidate, the lesser the desired effect, and the less likelihood of the drug to have some off-target effect. Kd is known as dissociation constant of drug. It measures the rate of dissociation of the drug and its binding affinity. Birabresib (MK8628), a BET inhibitor by Merck & Co., has IC50 value of 100nM.

About P & S Market Research

P & S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we're keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P & S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email:

Web:

Connect with us: | | |

MENAFN0702201800703653ID1096440818